From June 27, 2023 to June 30, 2023, the company has repurchased 119,382 shares, representing 0.09% for $0.15 million. With this, the company has completed the repurchase of 119,382 shares, representing 0.09% for $0.15 million under the buyback announced on June 27, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | 0.00% | -7.01% | +65.91% |
05-15 | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
05-15 | Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.91% | 184M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Tranche Update on Atossa Therapeutics, Inc.'s Equity Buyback Plan announced on June 27, 2023.